Abstract |
Currently, glioblastoma ( glioma) is described as the deadliest brain tumor for its invasive natural with exceeding difficulty in surgical excision. Blood-brain barrier (BBB) can restrict the penetration of most therapeutic reagents including platinum (Pt)-based drugs-the most widely used reagents in clinical trials for their revolutionized cancer chemotherapy against a broad range of tumors. Nanomedicine represents a promising strategy for the intravenous delivery of Pt-based drugs into the brain. In this research, with the aim of malignant glioma treatment by Pt-based drugs, a novel nano drug carrier was developed: dendrigraft poly-L-lysines (DGLs) was PEGylated, linked with diethylenetriaminpentaacetic acid ( DTPA) to complex (1,2-diaminocyclohexane)platinum(II) (DACHPt), and modified with Substance P (SP) as a BBB/ glioma dual-targeting moiety. The preparation and characterization of the platform were exhibited in detail. The increased targeting capability and antitumor effect was found both in vitro and in vivo. The well-defined chemical composition, rigorously nanoscaled size and the first attempt of using SP as a BBB/ glioma dual-targeting group were highlighted. The combined results suggest this strategy may serve as novel formulation for Pt-based drugs with the aim of clinical glioma treatment.
|
Authors | Tao Sun, Xutao Jiang, Qingbing Wang, Qinjun Chen, Yifei Lu, Lisha Liu, Yu Zhang, Xi He, Chunhui Ruan, Yujie Zhang, Qin Guo, Yaohua Liu, Chen Jiang |
Journal | ACS applied materials & interfaces
(ACS Appl Mater Interfaces)
Vol. 9
Issue 40
Pg. 34603-34617
(Oct 11 2017)
ISSN: 1944-8252 [Electronic] United States |
PMID | 28925679
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Blood-Brain Barrier
- Brain Neoplasms
- Cell Line, Tumor
- Drug Delivery Systems
- Glioma
- Humans
- Lysine
- Substance P
(chemistry)
|